Which of the following is most common adverse effect of zalcitabine: (AIIMS Nov 2011)
|B||Bone marrow suppression|
|D||Peripheral neuropathy transaminase levels|
a. Zalcitabine is a cytosine analogue reverse transcriptase inhibitor.
b. The major adverse events of zalcitabine administration are peripheral neuropathy, stomatitis, rash and pancreatitis.
c. Zalcitabine-associated peripheral neuropathy is dose related and is more common with pre-existing neuropathy and advanced disease. Alcohol consumption, diabetes and low vitamin B12 levels also are associated with an increased risk of zalcitabine-associated neuropathy. Severe neuropathy.
d. Symptoms include numbness, burning, and tingling of the feet. Stomatitis with ulceration of buccal mucosa, soft palate, tongue and pharynx occurs in 3% of patients and may resolve with continued therapy.
e. Pancreatitis is a rare complication of zalcitabine therapy. Mild and self-limited rash is common but rarely necessitates discontinuation of therapy. Other toxicities include arthralgias, myalgias, and elevated transaminase levels.